Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Hepatocellular 11Stomach Neoplasms 5Esophageal Squamous Cell Carcinoma 3Carcinoma, Non-Small-Cell Lung 3Ovarian Neoplasms 2Gastric Adenocarcinoma 2Cholangiocarcinoma 2Breast Neoplasms 2Biliary Tract Neoplasms 2Advanced Gastric Cancer 2Adenocarcinoma 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma 1Salivary Gland Neoplasms 1Radioactive Iodine-refractory Differentiated Thyroid Cancer 1Osteosarcoma 1Neuroblastoma 1Malignant Neoplasms of Digestive Organs 1Liver Neoplasms 1Gestational Trophoblastic Disease 1Gastrointestinal Stromal Tumors 1Fludzoparib" and Anti-angiogenic 1Colonic Neoplasms 1Cirrhosis, Familial, with Pulmonary Hypertension 1Advanced Primary Liver Cancer 1Advanced Biliary Tract Carcinoma 1Adebrelimab 1

Interventions

Cyclophosphamide 28Temozolomide 25Irinotecan 21dinutuximab 20Topotecan 15Magnetic Resonance Spectroscopy 13Specimen Handling 12Biopsy 12naxitamab 11Granulocyte-Macrophage Colony-Stimulating Factor 113-Iodobenzylguanidine 11Vincristine 10Etoposide 10sargramostim 9Melphalan 9Isotretinoin 9fludarabine 8X-Rays 8Colony-Stimulating Factors 8Carboplatin 8etoposide phosphate 7Phantoms, Imaging 7Doxorubicin 7fludarabine phosphate 6Stem Cell Transplantation 6Nuclear Medicine Department, Hospital 6Eflornithine 6Thiotepa 5Granulocyte Colony-Stimulating Factor 5Filgrastim 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroblastoma × apatinib × 1 year × Clear all
NCT05027386 2026-02-05

Apatinib Mesylate Combined With IT Regimen for the Treatment of Recurrent or Refractory Pediatric Neuroblastoma: A Single-arm, Phase I/II,Multi-center, Clinical Study.

Sun Yat-sen University

Phase 1/2 Recruiting
125 enrolled
CNS

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡